New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study.
Cancer
Cardiovascular events
Osteoporosis
Turner syndrome
Type 2 diabetes
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
09
02
2022
accepted:
27
06
2022
pubmed:
31
7
2022
medline:
15
11
2022
entrez:
30
7
2022
Statut:
ppublish
Résumé
Many questions concerning Turner syndrome (TS) remain unresolved, such as the long-term complications and, therefore, the optimal care setting for adults. The primary aim of this long-term cohort study was to estimate the incidence of comorbid conditions along the life course. A total of 160 Italian patients with TS diagnosed from 1967 to 2010 were regularly and structurally monitored from the diagnosis to December 2019 at the University Hospital of Bologna using a structured multidisciplinary monitoring protocol. The study cohort was followed up for a median of 27 years (IQR 12-42). Autoimmune diseases were the comorbid condition with the highest incidence (61.2%), followed by osteoporosis and hypertension (23.8%), type 2 diabetes (16.2%) and tumours (15.1%). Median age of onset ranged from 22 years for autoimmune diseases to 39 years for type 2 diabetes. Malignant tumours were the most prominent type of neoplasm, with a cumulative incidence of 11.9%. Papillary thyroid carcinoma was the most common form of cancer, followed by skin cancer and cancer of the central nervous system. Only one major cardiovascular event (acute aortic dissection) was observed during follow-up. No cases of ischaemic heart disease, heart failure, stroke or death were recorded. This cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
Identifiants
pubmed: 35907176
doi: 10.1007/s40618-022-01853-z
pii: 10.1007/s40618-022-01853-z
pmc: PMC9646560
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2247-2256Informations de copyright
© 2022. The Author(s).
Références
Hypertension. 2020 Nov;76(5):1608-1615
pubmed: 32895020
Obstet Gynecol. 1974 Aug;44(2):298-309
pubmed: 4608181
Lancet Oncol. 2008 Mar;9(3):239-46
pubmed: 18282803
J Bone Miner Res. 2000 Oct;15(10):2005-10
pubmed: 11028454
Int J Cardiol. 2021 Feb 15;325:127-131
pubmed: 33045278
Int J Cancer. 2016 Aug 15;139(4):754-8
pubmed: 27061708
J Clin Endocrinol Metab. 2001 Jul;86(7):3061-9
pubmed: 11443168
Endocrine. 2018 Mar;59(3):651-660
pubmed: 28593616
World Health Organ Tech Rep Ser. 1980;646:1-80
pubmed: 6771926
J Clin Densitom. 2019 Oct - Dec;22(4):453-471
pubmed: 31400968
Clin Endocrinol (Oxf). 2012 Dec;77(6):844-51
pubmed: 22233516
Endocr J. 2020 Oct 28;67(10):1023-1028
pubmed: 32554947
J Clin Endocrinol Metab. 2006 Oct;91(10):3897-902
pubmed: 16849410
Eur J Endocrinol. 2005 Oct;153(4):499-502
pubmed: 16189169
Laryngoscope. 1997 Jan;107(1):95-100
pubmed: 9001272
J Clin Endocrinol Metab. 2008 Jun;93(6):2109-14
pubmed: 18349057
Nat Rev Endocrinol. 2019 Oct;15(10):601-614
pubmed: 31213699
J Endocrinol Invest. 2022 Jun;45(6):1255-1263
pubmed: 35237949
Acta Clin Belg. 2022 Feb;77(1):86-92
pubmed: 32780684
J Negat Results Biomed. 2007 Dec 18;6:10
pubmed: 18088406
World Health Organ Tech Rep Ser. 1985;727:1-113
pubmed: 3934850
J Hypertens. 1993 Sep;11(9):905-18
pubmed: 8254173
J Am Heart Assoc. 2019 Jun 4;8(11):e011501
pubmed: 31131660
J Clin Endocrinol Metab. 2000 Sep;85(9):3199-202
pubmed: 10999808
Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76
pubmed: 15286277
Front Endocrinol (Lausanne). 2019 Jul 30;10:511
pubmed: 31417494
Eur J Med Genet. 2016 May;59(5):269-73
pubmed: 27058262
J Hypertens. 2003 Nov;21(11):1983-92
pubmed: 14597836
Diabetes Care. 1997 Jul;20(7):1183-97
pubmed: 9203460
Front Immunol. 2018 Oct 04;9:2279
pubmed: 30337927
Eur J Endocrinol. 2017 Sep;177(3):G1-G70
pubmed: 28705803
Osteoporos Int. 2021 Apr;32(4):671-680
pubmed: 32968889
Clin Exp Immunol. 2009 May;156(2):205-10
pubmed: 19298606
Climacteric. 2017 Oct;20(5):436-441
pubmed: 28523940
J Clin Endocrinol Metab. 2011 Sep;96(9):E1517-26
pubmed: 21752892
J Clin Endocrinol Metab. 2008 Dec;93(12):4735-42
pubmed: 18812477
Hypertension. 2003 Dec;42(6):1206-52
pubmed: 14656957
Endocr Rev. 2012 Oct;33(5):677-714
pubmed: 22707402
Endocr Rev. 2002 Feb;23(1):120-40
pubmed: 11844747
Br J Cancer. 1996 May;73(9):1156-9
pubmed: 8624281
Nat Rev Endocrinol. 2013 Dec;9(12):724-34
pubmed: 24126481
Clin Endocrinol (Oxf). 2007 May;66(5):744-51
pubmed: 17381484
Autoimmun Rev. 2020 Oct;19(10):102649
pubmed: 32805423
Lancet. 2018 Jun 16;391(10138):2449-2462
pubmed: 29916386
Clin Endocrinol (Oxf). 2000 Mar;52(3):363-70
pubmed: 10718835
Eur J Endocrinol. 2021 Jan;184(1):79-88
pubmed: 33112259
Eur J Endocrinol. 2019 Jun 1;180(6):397-406
pubmed: 30991358
Am J Med Genet A. 2005 Jun 1;135(2):150-4
pubmed: 15880570
Horm Res. 2005;64 Suppl 3:51-7
pubmed: 16439845
Maturitas. 2019 Dec;130:41-49
pubmed: 31706435
J Hypertens. 2007 Sep;25(9):1751-62
pubmed: 17762635
Arthritis Rheum. 2010 Mar;62(3):658-66
pubmed: 20187158
Can J Cardiol. 2020 May;36(5):596-624
pubmed: 32389335